利培酮合并氯氮平治疗难治性精神分裂症  

Risperidone combined with clozapine in treatment of refractory schizophrenia

作　　者：毛红岩[1] 徐莉莎[1] 

机构地区：[1]安徽省宿州市第二人民医院,宿州234000

出　　处：《临床医学》2013年第3期26-27,共2页Clinical Medicine

摘　　要：目的了解利培酮与氯氮平合并治疗难治性精神分裂症的疗效与安全性。方法 38例符合中国精神疾病分类方案与诊断标准第3版精神分裂症诊断标准,且临床判断属于难治性患者,给予利培酮合并氯氮平治疗,疗程为8周,分别在治疗前后进行阳性与阴性症状量表(PANSS)和副反应量表(TESS)评定。结果两药合并治疗8周后总有效率为73.7%,PANSS阳性、阴性及一般精神病理分值治疗前后比较差异均有统计学意义(P<0.01),TESS总分治疗前后比较差异无统计学意义(P>0.05)。结论利培酮合并氯氮平治疗难治性精神分裂症疗效肯定,安全性高,值得临床应用。Objective To evaluate the efficacy and security of risperidone combined with clozapine in treatment of refractory schizophrenia.Methods Thirty-eight patients diagnosed as schizophrenia according to CCMD-3 and proved to be refractory patients were treated with risperidonee and clozapin for eight weeks.Subjects were assessed with the PANSS and TESS before and after treatment.Results Overall successful rate after eights weeks was 73.7%.There were significant differences in the positive,negative and general psychopathology scores of PANSS between pre-and post-treatment（P0.01）.There was no significant difference in the TESS between pre-and post-treatment（P0.05）.Conclusion Risperidone combined with clozapine has positive effect and high security in treatment of refractory schizophrenic,and it is worthy of clinical application.

关 键 词：利培酮 氯氮平 难治性精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]